Self-Emulsifying Oral Topical Composition Bypassing First-Pass Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for conditions such as erectile dysfunction, type-2 diabetes, and other disorders related to serotonin dysregulation often require injectable forms that are cumbersome and costly, with significant plasma albumin binding and first-pass metabolism reducing efficacy and increasing dosing requirements.
Innovation Solution
A topical composition for transmucosal delivery in the oral cavity, comprising anhydrous suspensions with active agents like tadalafil, vardenafil, and GLP-1 receptor agonists, which self-emulsify to form liposomes and micelles, bypassing plasma albumin binding and first-pass metabolism, enhancing efficacy and reducing dosing needs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If injectable treatments are used for erectile dysfunction and type-2 diabetes, then treatment efficacy is improved, but treatment complexity and cost increase
Solution Approach 1:
The patent replaces the mechanical injection system with a topical oral composition that delivers active agents through the mucosal membrane. This substitution eliminates needles and injection procedures while maintaining effective drug delivery through the use of permeation enhancers and liposomal carriers that facilitate transmucosal absorption.
Solution Approach 2:
The patent introduces a topical composition as an intermediary delivery system that contains active agents, permeation enhancers, and liposomal carriers. This intermediary system bridges the gap between oral administration and direct bloodstream access, allowing drugs to bypass first-pass metabolism while avoiding injection complexity.
2Ease of operation
If oral medications are used, then ease of administration is improved, but first-pass metabolism reduces efficacy
Solution Approach 1:
The topical composition acts as an intermediary that enables oral administration to bypass first-pass metabolism. The composition includes permeation enhancers and liposomal carriers that facilitate direct transmucosal absorption into the bloodstream, maintaining the ease of oral administration while achieving the efficacy of parenteral delivery.
Solution Approach 2:
The patent changes the physical and chemical parameters of the drug delivery system by using liposomal carriers and permeation enhancers. These parameter changes enable the drug to traverse the mucosal membrane directly into the bloodstream, altering the absorption pathway to avoid hepatic first-pass metabolism while maintaining oral administration convenience.
3Reliability
If higher dosing is used to overcome plasma albumin binding, then treatment efficacy is maintained, but dosing requirements and cost increase
Solution Approach 1:
The liposomal carriers in the topical composition act as intermediaries that protect active agents from plasma albumin binding. The liposomes serve as protective vehicles that deliver drugs directly to target tissues, reducing the extent of albumin binding and allowing lower dosing requirements while maintaining treatment efficacy.
Solution Approach 2:
The patent changes the binding parameters of the active agents by using liposomal encapsulation. This parameter change reduces the affinity between drugs and plasma albumin, decreasing the amount of drug sequestered by albumin and thereby reducing the total dosing requirements needed to achieve therapeutic effects.
4Reliability
If topical compositions with complex formulations are used, then treatment efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent combines multiple functional components (active agents, permeation enhancers, liposomal carriers, and flavoring agents) into a single topical composition. This merging of functions into one formulation simplifies the manufacturing process compared to producing separate products for each function, while maintaining the complex therapeutic effects needed for effective treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The topical composition achieves effective treatment of erectile dysfunction, type-2 diabetes, and other conditions with reduced dosing requirements, improved efficacy, and lower patient costs by direct mucosal absorption, mimicking injectable benefits without their drawbacks.
Implementation Method 1
The anhydrous suspension is configured to self-emulsify in an aqueous environment of the oral cavity of the subject to form a mixed micelle and liposome delivery system
Implementation Method 2
transmucosal delivery of the tadalafil or vardenafil within the oral cavity
Data Source
AI summary
A method of treating erectile disfunction includes administering a pharmaceutically effective amount of a topical composition comprising an anhydrous suspension including tadalafil or vardenafil to an oral cavity of a subject for oral absorption therein. The topical composition is formulated to self-emulsify in an aqueous environment of the oral cavity.